Glenmark inks pact with Menarini Group to commercialise nasal spray in Europe
The company's product is a novel fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris(tm) Nasal Spray across numerous markets throughout Europe Glenmark Pharma share price rises nearly 3% on tentative approval from USFDA
The share touched its 52-week high of Rs 572.70 and 52-week low of Rs 168 on 22 June, 2020 and 13 March, 2020, respectively. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ("SEBI LODR")
This is in furtherance to our earlier letter, intimating you of issuance of a notice of optional redemption ('Notice') in respect of U.S $200 million 4.5% Senior Notes due 2021 ('2021 Notes') which are listed on the Singapore Exchange Securities Trading Limited, in accordance with the terms of the Indenture dated August 1, 2016, between, among others, the Company and Citicorp International Limited, as trustee; and also in furtherance of our letter dated 9 December 2020, in relation to the redemption of U.S.$182,500,000 in aggregate principal amount of the 2021 Notes, representing approximately 91.25% of the aggregate principal amount of the Notes at the time of initial listing. The Company wishes to inform that the Company has redeemed U.S. $7,500,000 in aggregate principal amount of its 2021 Notes, representing approximately 3.75% of the aggregate principal amount of the 2021 Notes at the time of initial listing. GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ("SEBI LODR")
This is in furtherance to our earlier letter, intimating you of issuance of a notice of optional redemption ('Notice') in respect of U.S $200 million 4.5% Senior Notes due 2021 ('2021 Notes') which are listed on the Singapore Exchange Securities Trading Limited, in accordance with the terms of the Indenture dated August 1, 2016 (as amended, supplemented, waived or otherwise modified from time to time), between, among others, the Company and Citicorp International Limited, as trustee. The Company wishes to inform that the Company has redeemed U.S. $182,500,000 in aggregate principal amount of its 2021 Notes, representing approximately 91.25% of the aggregate principal amount of the 2021 Notes at the time of initial listing. As on the date of this announcement, U.S. $ 17,500,000 in aggregate principal amount of the 2021 Notes remain outstanding. We request you to kindly take this intimation on record and to treat the same as compliance with the applicable provisions of the SEBI LODR. GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions on a consolidated basis drawn in accordance with the relevant accounting standards for the half year ended 30th September, 2020. GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ("SEBI LODR")
Further to our letter dated November 20, 2020, we wish to inform you that Glenmark Pharmaceuticals Limited ("Company") has issued a notice of optional redemption to the holders of U.S. $200 million 4.5% Senior Notes due 2021 ("Notice") listed on the Singapore Exchange Securities Trading Limited, in accordance with the terms of the Indenture dated as of August 1, 2016 (as amended, supplemented, waived or otherwise modified from time to time), between, among others, the Company and Citicorp International Limited, as trustee. Copy of the Notice is attached herewith. Glenmark Pharma share price gains on tentative USFDA nod for kidney cancer drug
The company has received FDA's tentative nod for Axitinib tablets in the strength of 1mg and 5 mg. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA tentative approval for Axitinib Tablets, 1 mg and 5 mg